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Scientific LifeHuman Heredity and Health in Africa (H3Africa) research
seeks to promote fair collaboration between scientists in
Africa and those from elsewhere. Here, we outline how
concerns over inequality and exploitation led to a policy
framework that places a firm focus on African leadership
and capacity building as guiding principles for African
genomics research.
Introduction
The historical underrepresentation of people of African
ancestry in genomics research [1,2], with only a few studies
focusing on or including people of African ancestry, has the
potential of widening the health gap between Africa and
the rest of the world by generating knowledge and inter-
ventions that may help in understanding or treating dis-
ease in Africa [3]. The H3Africa Consortium seeks to
harness genomics technologies to investigate diseases
pertinent to African patients [2]. Central to this aim is
fostering collaboration between scientists in Africa and
elsewhere. Of ethical importance is that H3Africa builds
equitable partnerships between researchers and other key
stakeholders. Equitable, or fair, partnerships can help
build strong research systems [4]. They are also a means
to counter exploitation and promote mutual respect and
trust [5], and offer an opportunity to ensure that research
is responsive to local health needs and that data interpre-
tation is contextualised.
H3Africa builds on a growing body of work seeking to
define what constitutes fair partnerships [6–10]. Here, we
outline four key components of that policy framework that
together seek to establish more ‘fair’ ways of working
together, most notably by advocating preferential access0168-9525/
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hope that these examples can set a new standard for
international collaborative health research that involves
samples and data from African patients.
African leadership
An important aspect of H3Africa research is that it is under
the leadership of scientists on the African continent, with
grants awarded to, and managed by, African institutions.
The expectation is that such research will be more success-
ful in capitalising on the insight and experience of African
clinicians and researchers, help in data interpretation and
translation of results to the clinical setting, and build
research capacity [2,6,7]. In the case of H3Africa, funding
was allocated exclusively to researchers with a primary
institutional affiliation in Africa, and the majority of co-
applicants also had to be based in Africa. In addition, the
majority of funds have to be spent in Africa. The H3Africa
Steering Committee comprises H3Africa lead investigators
(currently 23) and two representatives of the two funding
bodies that support it. Additional representatives of the
funding bodies join the meetings but do not have voting
rights. The effect is that African scientists are developing
the policies governing the genomic research taking place,
and that H3Africa is establishing a South-to-South net-
work (i.e., a collaboration network between scientists
based in the Global South) of genomic scientists, with
the academic discourse now occurring in Africa and be-
tween African scientists [11,12]. This is one recognised
element of fair partnerships [7,8].
The H3Africa policy framework
H3Africa has developed policies for sample and data shar-
ing, as well as the terms of reference for the committee
deciding on sample and data access [2]. The various poli-
cies were developed by several H3Africa Working Groups,
comprising representatives of each of the currently funded
21 research projects. These policies took about 12 months
to develop in an iterative process involving the workingTrends in Genetics, March 2015, Vol. 31, No. 3 117
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the H3Africa meetings. Policy proposals are pending
ratification by the H3Africa Steering Committee. The
policy framework offers three further examples of how
notions of fairness were incorporated in the work of the
Consortium.
The data-sharing policy
In line with international standards, H3Africa researchers
are required to make genomic data available for secondary
research. H3Africa researchers are granted a minimum of
11 months before genomic and phenotype data are publicly
released, after which the data are under publication em-
bargo for a further 12 months or until the first publication.
Therefore, the total timeframe for the public release of data
is 23 months. This is significantly longer than for other
projects funded by the same agencies*. The reason for this
extended period of exclusive access is to enable African
scientists to analyse and publish their data before others
can, and is similar to a previous large genomics research
project that occurred in Africa [13]. Training is currently
under way through H3A-BioNet, a continental bioinfor-
matics network that offers courses, mentorship, and infra-
structural support for the analysis of genomic data. In
addition to these extended timelines, applicants wishing
access to data need to describe how their proposed use will
contribute to capacity building and health improvement in
Africa. The hope is that, by prompting secondary users to
consider this, there will be greater awareness of the need
to establish a more fair way of working with researchers in
Africa.
The sample-sharing policy
A prominent ethical concern in research in Africa relates
to ownership over samples and, to a lesser extent, data.
Samples and their movement across borders seem to
have become symbolic of concerns over exploitation
and fairness and, therefore, have become stringently
regulated in many African countries [14]. Examples of
regulatory approaches are strict export criteria, and
requirements for export permits and material transfer
agreements.
The proposal that samples collected in H3Africa need to
be shared for secondary use through one of the H3Africa
biorepositories in development, has created considerable
controversy. This proposal generated suspicions that
H3Africa research is just a way of making available
African samples to researchers elsewhere. To address
such concerns, careful thought has gone into developing
a policy framework that would not only allay such fears,
but also promote African-led research on African samples.
The current policy proposal is that external researchers
can apply for samples but, for a period of 3 years, they will
only be made available either to researchers based in
Africa, or to researchers outside of Africa who both work
with researchers in Africa and develop a clear plan for
capacity building. In other words, for 3 years, samples can*See the Draft NIH Data Sharing Policy available from http://grants.nih.gov/grants/
guide/notice-files/NOT-OD-13-119.html. For information about the Wellcome Trust
position, see http://www.wellcome.ac.uk/About-us/Policy/Spotlight-issues/
Data-sharing/Guidance-for-researchers/index.htm (both accessed 3 December 2014)
118only be used for research that strengthens African
research capacity. Unlike data, biospecimens are a limited
resource that can be depleted, so careful consideration is
required when providing access to these. Integrated into
the policy is a requirement for new data generated from
these samples to be submitted to the same public reposi-
tory as H3Africa data.
The data and biospecimen access committee
A final component of the policy framework where consid-
erations of fairness have been discussed is the composition
of the committee that will decide on access requests: the
Data and Biospecimen Access Committee (DBAC). Given
that the DBAC will control access to African samples,
H3Africa researchers felt that it was necessary for this
committee to comprise primarily individuals based in
Africa, but that it could also include researchers outside
of Africa with experience working in Africa, to allow rele-
vant expertise from across the world to be brought to bear.
Ideally, the DBAC should have representation from across
relevant scientific disciplines, such as genomics, bioinfor-
matics, and ethics, as well as nonscience stakeholders,
such as a patient advocate.
The future of genomic research in Africa
The focus on Africa seeks to ensure that African research-
ers have a fair chance to develop the capacity for genomic
research and investigate diseases that they believe are
pertinent to Africa. It also seeks to ensure that data will be
interpreted in the context where they were collected. We
hope that H3Africa will set a new gold standard for col-
laborative genomic research in Africa, and possibly for
broader collaborative health research.
The exclusive focus on the ‘Africanness’ of researchers in
their various roles (as primary applicants, secondary data
and sample users, or members of the DBAC) of course
raises important questions, both about what ‘Africanness’
really means, and about the ethical implications of restrict-
ing the utility of samples and data in this way. What should
matter is that research that is conducted is of the highest
ethical and scientific standard and leads to maximum
patient benefit in the shortest period of time, regardless
of where the research is conducted. This should be based on
principles of fairness and inclusivity. The question is
whether H3Africa policies will successfully and sustain-
ably foster African-led genomic research, and build a gen-
eration of African scientists that are internationally
competitive.
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